cropper
National Cannabis Newswire
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
November 18.2026
3 Minutes Read

Navigating Today's Cannabis Stocks: Insights for Professionals

Cannabis Stocks Today — Wednesday 18 November 2026: AFC Gamma holds above $3.50

Current Market Dynamics: A Closer Look at Cannabis Stocks

As of Wednesday, cannabis equities remained slightly lower, revealing signs of a cautious market as pre-market trading trends continue to shape investor sentiment. Notably, the AdvisorShares Pure US Cannabis ETF (MSOS) closed at $3.65, marking a decline of 1.08% from the previous day. Meanwhile, the Amplify Alternative Harvest ETF (MJ) settled at $20.47, down 1.68%. With a total of 35 tickers monitored in our daily coverage, the breadth of movement reflects a challenging environment: seven stocks recorded gains, two were stable, and a significant 26 dropped.

Leading the gainers was AFC Gamma (AFCG), with an impressive jump of 13.92% to reach $3.52. In contrast, Glass House Brands (GLASF) faced the steepest decline, dropping 12.40% to $2.26. This disparity points to a broader trend where some companies are adapting and thriving, while others struggle amidst changing market conditions.

Understanding the Numbers: Insights from Recent Performance

The financial performance of various cannabis stocks provides important insights into current industry trends. For instance, Glass House's recent earnings report showcased a revenue jump to $56.8 million from $26.2 million year-over-year, spurred by a record biomass production of about 319,000 pounds. Yet, these figures come with caveats; their gross margin narrowed to 26% from 34% in the previous quarter, suggesting the need for a careful interpretation of growth amid pricing pressures and a competitive marketplace.

AFC Gamma's continued firming above $3.50 highlights a recovery trajectory, especially after crossing its 50-day moving average during trading. This suggests a positive trend in investor confidence, although the absence of notable company announcements makes the source of this optimism intriguing. In contrast, Corbus Pharmaceuticals, trading at $3.01, is focusing on its new drug trial for obesity, emphasizing innovation even during market dips.

Future Outlook: What Lies Ahead for Cannabis Equity Investors?

With the cannabis market being as dynamic as it is, investors face a range of possibilities influenced by evolving regulations, public perception, and financial performance. The potential for legislative changes regarding cannabis legality continues to loom large, which could radically alter market conditions. For example, states like New Mexico and Arizona are witnessing strong dispensary growth, indicating increased consumer acceptance and demand.

As professionals in the cannabis industry, staying informed about these fluctuations will arm investors with the insights needed for better decision-making. For example, should more states move toward legalization, stocks in consistently performing companies like AFC Gamma could see enhanced valuations in the future.

Taking Action: Navigating the Cannabis Investment Landscape

For executive cannabis professionals, understanding market movements entails more than following stock price shifts. Recognizing the broader implications—regulatory considerations, public health narratives, and changing consumer patterns—offers a holistic view of the investment landscape.

As investor sentiment can change rapidly, proactive professionals should not only keep an eye on stock price movements but also foster connections within the cannabis community. This network can provide valuable insights, emerging trends, and grassroots perspectives that may not be captured through financial reports alone.

Your Opportunity: Stay Engaged and Informed

As the cannabis sector evolves, so too do the opportunities for growth. Engaging with your local cannabis community, attending industry conferences, and leveraging professional networks can amplify your presence in the field. Embrace the human stories that define our industry—it is these very narratives that enrich our understanding and empower our investment strategies.

In conclusion, while the current market presents challenges, it is also brimming with opportunities for informed professionals ready to adapt and thrive. Consider joining local advocacy groups or attending forums to remain on the cutting edge of industry developments.

Brands

0 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

Boots Launches SureLeaf: The First UK High-Street Medical Cannabis Service

Update Boots' Revolutionary Step into Medical CannabisBoots has made headlines by launching SureLeaf, a private medical cannabis service aimed at patients suffering from chronic pain, anxiety, and insomnia. This initiative marks a significant milestone as it is the first of its kind to be offered at a high-street pharmacy in the UK. With this innovative service, Boots is paving the way for accessible treatment options that can provide relief to those who have found limited success with traditional care methods.A Comprehensive Approach to Patient CareThe SureLeaf service provides a clear path for patients aged 25 and older to explore medical cannabis as a therapeutic option. The process begins with an online assessment that determines eligibility for either flower or oil forms of cannabis. This initial evaluation is crucial in ensuring that only suitable candidates proceed to the next stage: a video consultation with a qualified doctor from the General Medical Council's Specialist Register. Emphasizing patient safety, the proposed prescriptions undergo stringent review by a multidisciplinary clinical team, which includes a second independent consultant.Monitoring Patient Well-beingBoots has committed to closely tracking the health and progress of its patients. After beginning treatment, individuals can expect follow-up appointments after 28 days, with regular check-ins at least every three months. Clinicians will employ standardized questionnaires to assess changes in symptoms, quality of life, anxiety levels, sleep quality, and mood. This robust approach ensures that prescribing decisions are tailored to individual needs, addressing concerns that medical cannabis use may not be suitable for everyone.Collaboration with the University of NottinghamIn a bid to enhance the effectiveness and reliability of this new service, Boots has announced a collaboration with the University of Nottingham. This partnership will focus on research into patient outcomes and prescribing practices. Through this initiative, Boots is demonstrating its dedication to responsible medical cannabis use backed by empirical data—an essential factor in dispelling myths and fostering acceptance within the broader healthcare community.Eligibility Criteria: Who Can Benefit?The SureLeaf service will cater to those diagnosed with chronic pain conditions such as fibromyalgia, neuropathic pain, osteoarthritis, and more, as well as mental health conditions like general anxiety and insomnia. Notably, candidates must have previously attempted conventional treatments without achieving satisfactory relief, allowing this service to stand as a beacon of hope for many who feel overlooked by traditional healthcare methods.A Future for Medical Cannabis in RetailBoots’ entry into the medical cannabis landscape could set a precedent for future retail pharmacy practices across the UK. As healthcare evolves, the public’s perception of cannabis as a legitimate medical treatment is gradually changing. With more high-street pharmacies considering similar initiatives, patients might find it increasingly easier to access vital treatments without navigating the complexities of specialty clinics.This service exemplifies a broader trend towards integrating cannabis into mainstream healthcare. As legislation continues to evolve and societal attitudes shift, it is likely that the connection between health and cannabis will become an integral part of community wellness strategies.For cannabis professionals, this development signifies an era of opportunity to explore how retail can play a pivotal role in patient care. Keeping an eye on the outcomes of Boots' SureLeaf may provide valuable insights for those in the industry who are advocating for similar services in their own communities.

Dutch Government Reevaluates Edibles: A Turning Point for Cannabis Regulation

Update The Growing Debate Over Edibles in Dutch CoffeeshopsIn a notable shift for the Dutch cannabis landscape, the government is revisiting the use of edibles within its controlled cannabis supply chain experiment. This decision comes under increasing parliamentary pressure, particularly from three Christian parties advocating for change. Despite concerns voiced during a Tweede Kamer committee debate, Minister of Health Sophie Hermans has defended the initiative, emphasizing the necessity for scientific evidence before enacting any prohibitive measures.During the hearing, attendance was notably sparse, highlighting a tangible divide in the parliament, with the left largely absent due to an ongoing government crisis. The Christian Democrats (CDA), Reformed Political Party (SGP), and ChristenUnie were the main bodies calling for a re-evaluation of the pilot with a focus on the alarming increase in the prevalence of edibles in participating coffeeshops—from a staggering 20% to as high as 90% in some locations, according to CDA MP Tijs van den Brink.Why Edibles Matter in Cannabis RegulationEdibles have become a central issue in the ongoing discussion about the normalization of cannabis in the Netherlands. While the increase in sales might seem alarming to some, proponents argue that these products can offer a safer alternative by eliminating the harmful effects associated with smoking. This consideration was notably absent during the debate, where the focus remained primarily on regulation and potential harms of edibles.The Minister has indicated a commitment to allowing a similar product range as existing coffeeshops, making the ongoing assessment pivotal for understanding the effects and safety of these products. The absence of a THC cap on edibles further complicates the landscape, with health experts and policymakers alike calling for better standards and regulations as the pilot progresses.Future Directions: Racquetting Regulations and Health AccountabilityThe Dutch government is not only re-evaluating edibles but also scrutinizing the involvement of the tobacco industry within the cannabis supply framework. The troubling connection—exemplified by Altria’s stake in Cronos Group—has sparked discussions about consumer safety and corporate influence in a sector meant to promote public health.Minister Hermans is poised to make amendments to product regulations, ensuring that packaging will reflect certified THC levels. A thorough scientific exploration by the Trimbos Institute on high-THC products is expected to shed light on risk factors and guide future actions as the cabinet prepares a dedicated letter on edibles for later next year.Engaging in the ConversationThe ongoing discussion surrounding edibles and cannabis regulation offers cannabis industry professionals a unique opportunity to engage with both health advocates and policymakers. Understanding the potential benefits can help in creating a balanced narrative that emphasizes safe consumption and generates trust within the community. As regulations evolve, industry leaders must advocate for responsible governance that prioritizes health and consumer safety.Join the Advocacy for Responsible Cannabis PracticesThis evolving discourse calls for the active voices of cannabis professionals to participate in building a safer and more informed community. By supporting evidence-based regulations, we can ensure the cannabis industry remains rooted in health, safety, and responsible use. Let's join together to foster meaningful change in the cannabis landscape!

How Telemedicine is Redefining Germany's Medical Cannabis Market and What It Means for Professionals

Update Unlocking Access: The Role of Telemedicine in Medical CannabisGermany's medical cannabis landscape is undergoing a significant transformation, driven largely by the advent of digital health technologies. This evolution not only simplifies patient access to medical cannabis but also presents unique challenges shaped by complex legal frameworks. The introduction of telemedicine into this domain has drastically reduced geographical barriers, allowing patients to consult with physicians and receive necessary prescriptions from the comfort of home. Despite these advancements, navigating the intricacies of legal compliance remains vital for companies involved in this burgeoning market.The Complex Legal LandscapeThe regulatory environment surrounding medicinal products in Germany is intricately woven with EU laws and national guidelines. Telemedicine has been endorsed as a legitimate treatment method, yet physicians face stringent requirements before prescribing medical cannabis online. Since legislative reforms in 2018, doctors can conduct consultations via telemedicine, provided they can adequately assess a patient’s situation without a physical examination. This adaptability is crucial; however, for cases where a remote assessment is inadequate, an in-person visit remains mandatory. This ensures that the standards of care are upheld while leveraging technology.Cross-Border Telemedicine: Opportunities and ChallengesThe European Court of Justice has clarified that physicians licensed in one EU member state can generally provide telemedical services across borders, including to patients in Germany. This ruling opens doors for healthcare practitioners specializing in medical cannabis to expand their reach. However, telemedicine platforms must carefully evaluate the specific legalities in both their home country and Germany to operate effectively. The differentiation between practitioners from EU member countries and those from outside the EU presents both opportunities and complexities. While European professionals can offer services without requiring a German license, this is not the case for non-EU practitioners, making legal counsel critical for operational effectiveness.Navigating Advertising RegulationsThe advertising landscape for telemedicine services is equally nuanced. Legal questions remain about the applicable laws for cross-border advertising and how they relate to the country-of-origin principle. While physicians can advertise their telemedicine services throughout Europe under the Freedom to Provide Services, clarity is still needed regarding compliance with local advertising regulations. It is important for platform operators and service providers to seek localized legal advice to ensure their marketing efforts adhere to the laws relevant to the specific jurisdiction they are targeting.Looking Ahead: Trends and PredictionsAs digital health continues to evolve, so too will the regulations governing medical cannabis and telemedicine in Germany and beyond. The integration of technology into healthcare is likely to prompt further legislative reforms that facilitate easier access while ensuring patient safety. Companies and professionals in the cannabis industry need to stay informed about these changes and anticipate new regulations that may affect market entry, advertising strategies, and patient care methods. By remaining proactive and knowledgeable about these dynamics, they can better navigate the evolving landscape and contribute to a more accessible and patient-centered healthcare system.As the synergy between technology and healthcare deepens, understanding these developments becomes increasingly essential—not only for cannabis professionals but also for the patients who rely on these services. The intricate balance between innovation, regulation, and patient welfare underscores the need for ongoing dialogue and legal guidance.

National Cannabis Newswire
National Cannabis Newswire keeps you informed, empowered, and connected to the Cannabis community.

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

480.878.1919

AVAILABLE FROM 8AM - 5PM PST

Contact

11504 W Piccadilly Rd,
Avondale, AZ 85392,

ABOUT US

Your source for breaking cannabis industry news, expert insights, and nationwide updates—National Cannabis Newswire keeps you informed, empowered, and connected.

© 2026 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*